Journal
LUPUS
Volume 24, Issue 4-5, Pages 351-363Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0961203314556139
Keywords
Systemic lupus erythematosus; T cells; interleukin-2 (IL-2); epigenetics; treatment
Categories
Funding
- National Institutes of Health [PO1 AI065687, RO1 AI49954, RO1 42269]
- SICPA Foundation
Ask authors/readers for more resources
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by a loss of tolerance to multiple endogenous antigens. SLE etiology remains largely unknown, despite recent insight into the immunopathogenesis of the disease. T cells are important in the development of the disease by amplifying the immune response and contributing to organ damage. Aberrant signaling, cytokine secretion, and tissue homing displayed by SLE T cells have been extensively studied and the underlying pathogenic molecular mechanisms are starting to be elucidated. T-cell-targeted treatments are being explored in SLE patients. This review is an update on the T-cell abnormalities and related therapeutic options in SLE.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available